Navigation Links
PRT054021 in Medical Technology

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

...ulants, determined that EXPERT met its objectives: prt054021 appeared effective and safe at the two doses studi... look forward to studying the unique properties of prt054021 in additional clinical trials." About prt054021 - Portola's Factor Xa Inhibitor ...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

...tled "Evaluation of the Factor Xa (FXA) Inhibitor, prt054021 (PRT021), against Enoxaparin in Randomized Trial f...0 p.m. (CEST) in the exhibition area. About prt054021 -- Portola's Factor Xa Inhibitor prt054021 is an oral Factor Xa inhibitor, an anticoagulant i...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

...replacement (TKR) surgery. Portola expects to move prt054021 into Phase III clinical development in VTE prevent... compare the safety and antithrombotic activity of prt054021 with that of enoxaparin. A steering committee of l... concluded that EXPERT met its objectives and that prt054021 was safe and effective at the doses studied. ...
PRT054021 in other areas

Healthcare Sales & Marketing Network News: Portola Pharmaceuticals ...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery (HSMN ...

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention ...

Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for ... Drug: PRT054021. Phase II. Study Type: Interventional. Study Design: ...

医药工业研究院_新闻中心

Based on these results, Portola will advance PRT054021 into further clinical testing. ... PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being ...

Phase II Study Of Factor Xa Inhibitor Gives Positive Results, Drug ...

... announced positive Phase II data on its lead compound, PRT054021, an oral Factor Xa inhibitor. ... expects to move PRT054021 into Phase III clinical ...

Portola Announces Positive Data on Factor Xa Inhibitor in VTE Trial

Portola Pharmaceuticals has received positive results from EXPERT, a Phase II study of its oral Factor Xa inhibitor, PRT054021, for the prevention of venous ...

Portola Pharmaceuticals, Inc. Announces Positive Phase II EXPERT ...

PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being ... In addition, PRT054021 is not excreted in the kidneys and therefore will not ...
Other Tags
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... the Atlanta Journal Constitution, the new Lifetime reality series, “Atlanta Plastic” is getting ... and who receives plastic surgery, with its predominantly African-American cast of doctors and ...
(Date:8/3/2015)... Los Angeles, California (PRWEB) , ... August 03, ... ... the Fifth Circuit Court of Appeals ruled in favor of the firm’s client ... Act ), North Cypress Medical Center must reimburse benefits for Hamsher’s residential treatment ...
(Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
(Date:8/3/2015)... ... , ... Dental practice in Los Angeles , Sunset Plaza Dental, is ... general health emergencies, such as broken arms or a heart attack, should be evaluated ... to during a dental emergency. This is important, because dental trauma is extremely common. ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
Other Contents